




Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Complete If Known	
		Application Number	10/790,260
		Filing Date	03-02-2004
		First Named Inventor	Pascal DESMAZEAU, et al
		Group Art Unit	1654
		Examiner Name	LUKTON, David
Sheet	2	of	3
		Attorney Docket Number	ST98007 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		ATKINSON G. et al., How To Show That Unicorn Milk Is A Chronobiotic: The Reagression-to-the-Mean Statistical Artifact, Chronobiology International (2001, pp. 1041-1053, Volume 18, No. 6) Abstract Only	
		BEZEAU S. et al., Statistical Power And Effect Sizes Of Clinical Neuropsychology Research, Journal of Clinical Experimental Neuropsychology (2001, pp. 399-406, Volume 23, No. 3) Abstract Only	
		BOLTON S., Independence and Statistical Inference In Clinical Trial Designs: a Tutorial Review, Journal Clinical Pharmacology (1998, pp. 408-412, Volume 38, No. 5) Abstract Only	
		BRYANT TN, The Presentation Of Statistics, Pediatric Allergy Immunology (1998, pp. 108-115, Volume 9, No. 3) Abstract Only	
		CHUNG KC et al., The Prevalence Of Negative Studies With inadequate Statistical Power: An Analysis Of The Plastic Surgery Literature, Plastic and Reconstructive Surgery (2002, pp. 1-6, Volume 109, No. 1) Abstract Only	
		DORIT AVRAHAMI et al., Effect of Multiple Aliphatic Amino Acids Substitutions on the Structure, Function, and Mode of Action of Diastereomeric Membrane Active Peptides, Biochemistry (2001, pp. 12591-12603, Volume 40)	
		ELISABETTA GAVINI et al., Synthesis and "In Vitro" Antimicrobial Properties of N-Oxide Derivatives Based on Tricyclic Indeno[2,1-c] pyridazine and Benzo[f] cinnoline systems, Arch. Pharm. Pharm. Med. Chem. (2000, pp.341-346, Volume 333)	
		JOHN LUDBROOK, Statistics In Physiology And Pharmacology: A Slow And Erratic Learning Curve, Clinical And Experimental Pharmacology and Physiology (2001, pp. 488-492, Volume 28)	
		P. JUVVADI et al., Structure-activity studies of normal and retro pig cecropin-melittin hybrids, Journal of Peptide Research (1999, pp. 244-251, Volume 53)	

Examiner Signature		Date Considered	9-26-05
-----------------------	---	--------------------	---------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.


Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/790,260	
			Filing Date	03-02-2004	
			First Named Inventor	DESMAZEAU	
			Group Art Unit	1654	
			Examiner Name	LUKTON, David	
Sheet	3	of	3	Attorney Docket Number	ST98007 - US - CNT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL		RONNIE WILLENHEIMER, Statistical Significance Versus Clinical Relevance in Cardiovascular Medicine, Progress in Cardiovascular Diseases (2001, pp. 155-167, Volume 44, No. 3)	
↓		RYOSUKE FUDOU et al., Haliangicin, a Novel Antifungal Metabolite Produced by a Marine Myxobacterium, The Journal of Antibiotics (2001, pp. 149-152, Volume 54, No. 2)	
DL		VERONIQUE BLANC et al., Cloning and Analysis of Structural Genes from Streptomyces pristinaespiralis Encoding Enzymes Involved in the Conversion of Pristinamycin II beta to Pristinamycin II a (PIIA): PIIA Synthase And NADH: Riboflavin 5'-Phosphate Oxidoreductase, Journal of Bacteriology (1995, pp. 5206-5214)	

Examiner Signature		Date Considered	9-26-05
-----------------------	---	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.